{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-335073","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2026-08-05T20:07:47+00:00","discovered_at":"2026-08-05T20:09:00.248288+00:00","generated_at":"2026-08-05T20:10:40.145031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Biomea Fusion Q2 net loss $8.3M, cash $35.2M; T1D C-peptide data positive","bullets":["Net loss of $8.3M for Q2 2026, down from $20.7M in Q2 2025; cash $35.2M as of June 30, 2026.","Cash runway projected into Q2 2027.","Phase II COVALENT-211 (T2D insulin-deficient) data expected Q1 2027; COVALENT-212 (T2D on GLP-1 RA) data expected Q2 2027.","Phase I GLP-131 (BMF-650 obesity) initial 28-day weight reduction data expected Q3 2026.","T1D data: 52% increase in mean C-peptide AUC at Week 12 with icovamenib 200 mg; planning Phase II trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-335073","json":"https://secwatch.observer/filing/0001193125-26-335073.json","markdown":"https://secwatch.observer/filing/0001193125-26-335073.md","text":"https://secwatch.observer/filing/0001193125-26-335073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/0001193125-26-335073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312526335073/bmea-20260805.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-05T20:10:40.145031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}